Announcements Trials
Browse Landscape

Phase

Phase 2 26Phase 1 8Phase 3 6Phase 4 3Phase 1/2 2Phase 2/3 1

Status

Withdrawn 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

NET 2Gastrointestinal 2Endocrine 2Genitourinary 1Dermatologic 1

Conditions

Prostatic Neoplasms 1Pituitary Neoplasms 1Pituitary ACTH Hypersecretion 1Pancreatic Neoplasms 1Pancreatic Fistula 1Neuroendocrine Tumors 1Neoplasms 1Melanoma 1Hypoglycemia 1Gastro-enteropancreatic neuroendocrine tumor 1Dumping Syndrome 1Acromegaly 1

Interventions

Dexamethasone 56Metformin 50Cyclophosphamide 47Saline Solution 39Cytarabine 37Cisplatin 36Zoledronic Acid 34Letrozole 34Carboplatin 33Sodium Chloride 32Bupivacaine 31Docetaxel 30Bevacizumab 30Vincristine 29Methotrexate 29Fluorouracil 28Propofol 27Capecitabine 27Fentanyl 26Doxorubicin 26Rituximab 25Drug Therapy 25Dexmedetomidine 25Prednisone 23Paclitaxel 23Oxaliplatin 21Morphine 21Gemcitabine 21Radiotherapy 19Prednisolone 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 4 × Interventional × pasireotide × Clear all
NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

RECORDATI GROUP

Phase 4 Completed
337 enrolled 8 charts
DermatologicEndocrineGenitourinaryNET

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

NCT02779257 2022-03-04

Pasireotide Treatment for Neuroendocrine Tumor

University of Maryland, Baltimore

Phase 4 Withdrawn
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Hypoglycemia

NCT02775227 2020-08-24

HYPAR

Helsinki University Central Hospital

Phase 4 Active not recruiting
126 enrolled
Gastrointestinal

Pancreatic Fistula, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡